December 2, 2020

Volume X, Number 337


December 01, 2020

Subscribe to Latest Legal News and Analysis

November 30, 2020

Subscribe to Latest Legal News and Analysis

FY 2016 Medical Device User Fees Announced

On August 3, 2015, the FDA announced the medical device user fee rates and payment procedures for fiscal year (“FY”) 2016, which applies from October 1, 2015 through September 30, 2016. The Agency will raise user fee rates by over 4%.

Under the Federal Food, Drug, and Cosmetic Act, as amended by the Medical Device User Fee Amendments of 2012 (“MDUFA III”), FDA is authorized to collect user fees for certain medical device submissions as well as annual fees for periodic reports of class III devices and registration for certain establishments. A qualified applicant may pay a lower “small business” fee; however, there is no reduction in the establishment registration fee for small businesses. FDA’s announcement and guidance, “FY 2016 Medical Device User Fee Small Business Qualification and Certification,” also issued on August 3, contains information on how to qualify as a small business for the purposes of medical device user fees. Additionally, FDA’s announcement includes information concerning the procedures for paying fees.

The fee rate for each submission type is based upon a specified percentage of the standard fee for a premarket application (“PMA”). The following are the FY 2016 standard user fees:

  • PMA: $261,388

  • Panel-track supplement: $196,041

  • 180-day supplement: $39,208

  • Real-time supplement: $18,297

  • 510(k) premarket notification submission: $5,228

  • 30-day notice: $4,182

  • 513(g) request for classification information: $3,529

  • Annual fee for periodic reporting on a class III device: $9,149

  • Annual establishment registration fee: $3,845

According to the Agency’s announcement, the fee you must pay is the fee that is in effect on the later of the date that your application is received by the Agency or the date your fee payment is recognized by the U.S. Treasury.

© 2020 Covington & Burling LLPNational Law Review, Volume V, Number 218



About this Author

Chris Hanson, Food and Drug Attorney, Covington Law Firm

Christopher Hanson advises international and domestic clients on regulatory strategies and compliance for medical devices, pharmaceuticals, biological products, cosmetics, animal products, and radiation-emitting electronic products. His broad range of clients include large multinational companies, venture capital firms, industry associations, clinical laboratories, and development-stage companies.

Mr. Hanson has extensive experience counseling clients on interactions with state, federal, and foreign regulatory agencies, including the Food and Drug Administration (...